| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Podoplanin (PDPN) is a platelet aggregation-inducing mucin-like sialoglycoprotein that is highly expressed in many cancers and normal tissues. PDPN has also been reported to be a marker to enrich tumor-initiating cells. Recently, we established the platform to produce a cancer-specific mAb (CasMab) by combining glycobiology and cell engineering technologies. In this study, we also established glycan-deficient CHO-S and HEK-293T cell lines, using the CRISPR/Cas or TALEN. We investigate several novel cancer-specific anti-PDPN or anti-glycopeptide mAbs. Antitumor activity of chimeric anti-human PDPN antibodies were validated. The CasMab-producing platform could lead to establishment of the side effect-reducing mAbs.
|
